Business Description
Trevena Inc
NAICS : 325412
SIC : 2834
ISIN : US89532E1091
Description
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.91 | |||||
| Equity-to-Asset | -0.19 | |||||
| Debt-to-Equity | -4.73 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -22.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -25.9 | |||||
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 17 | |||||
| 3-Year FCF Growth Rate | 14.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.75 | |||||
| 9-Day RSI | 54.71 | |||||
| 14-Day RSI | 50.7 | |||||
| 6-1 Month Momentum % | -32.15 | |||||
| 12-1 Month Momentum % | -77.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.66 | |||||
| Quick Ratio | 4.66 | |||||
| Cash Ratio | 4.37 | |||||
| Days Inventory | 192.13 | |||||
| Days Sales Outstanding | 20.91 | |||||
| Days Payable | 454.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.3 | |||||
| Shareholder Yield % | -141.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.53 | |||||
| Operating Margin % | -1129.25 | |||||
| Net Margin % | -1289.25 | |||||
| FCF Margin % | -1057.12 | |||||
| ROE % | -640.99 | |||||
| ROA % | -95.21 | |||||
| ROIC % | -434.08 | |||||
| ROC (Joel Greenblatt) % | -686.97 | |||||
| ROCE % | -105.03 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.59 | |||||
| EV-to-EBIT | -0.3 | |||||
| EV-to-EBITDA | -0.31 | |||||
| EV-to-Revenue | 3.54 | |||||
| EV-to-Forward-Revenue | 7.35 | |||||
| EV-to-FCF | -0.34 | |||||
| Earnings Yield (Greenblatt) % | -333.33 | |||||
| FCF Yield % | -429.3 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers